Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of piribedil on vigilance and cognitive function in Parkinson's disease
2009-012419-16Phase 3Completed
- Sponsor
- Desitin Arzneimittel
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of piribedil in Parkinson's disease (PD) (2 arms), sponsored by Desitin Arzneimittel. Primary endpoint: Median reaction time during minutes 16–30 in TAP vigilance subtest (moving bar, visual condition). Started Oct 2009; status: completed.
02
Drugs
piribedil
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2009-012419-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012419-16.